Resolutions of the Ordinary General Meeting of BioNTech 2022 | News

  • Helmut Jeggle re-elected Chairman of the Supervisory Board
  • Prof. Dr. Anja Morawietz and prof. dr. Rudolf Staudigl complements the existing management to reflect the company’s development
  • Proposed by the Management Board and the Supervisory Board, the special dividend of EUR 2.00 per ordinary share has been approved by the shareholders

MAINZ, Germany, June 1, 2022 (GLOBE NEWSWIRE) – At the annual general meeting BioNTech SE (Nasdaq: BNTX, “BioNTech” or “Company”), held on June 1, 2022, shareholders voted to re-elect incumbent chairman Helmut Jeggle to the Supervisory Board. The resolution was adopted with a majority of 96.44%. At the meeting after the Ordinary General Meeting, the Supervisory Board re-elected Helmut Jeggle as the Chairman. Moreover, with prof. dr hab. Anja Morawietz and prof. dr. Rudolf Staudigl appointed two more members to the Supervisory Board with a majority of 99.85 percent, respectively. and 99.86 percent. All three members will hold office for the General Meeting of Shareholders in 2026.

In addition, as proposed by the Management and Supervisory Boards, the shareholders decided to pay a special dividend of EUR 2.00 per common share (including shares held in the form of US Deposit Shares). This corresponds to approximately EUR 484.2 million, based on shares outstanding and entitled to dividends as of May 30, 2022.

“Over the past two years, BioNTech has evolved into a fully integrated biotechnology company with a diversified clinical pipeline, with several product candidates at later stages of development. We would like to share our success with our shareholders through a special dividend and buyout of shares in the 2021 program. This is in line with BioNTech’s capital allocation strategy and the company’s commitment to creating sustainable value for our shareholders, “he said. Helmut Jeggle, President of the Management Board of BioNTech. “With prof. Anja Morawietz, PhD and prof. Dr. Rudolf Staudigel, we strengthen the existing competences of our supervisory board in the areas of finance, enterprise management and international markets. I am immensely grateful for the opportunity to continue supporting this as Chairman of the Supervisory Board. “

Helmut Jeggle has been the CEO of BioNTech since 2008. He is CEO and founder of Salvia GmbH, a family business focused on investment in deep technology and science. In 2015-2021 he was the General Partner at ATHOS KG, an investment fund of the Strüngmann family. Previously, he was Head of Direct Investments at ATHOS Service GmbH and held various positions at Hexal AG. Helmut Jeggle is a member of supervisory boards in Germany and abroad, incl. at 4SC AG, AiCuris AG and tonies SE.

Prof. Dr. Anja Morawietz is Professor of External Accounting and General Business Management at the Nuremberg University of Applied Sciences Georg Simon Ohm. He has in-depth knowledge of accounting and auditing. Her research focuses on financial and sustainable reporting as well as corporate governance development.

Prof. Dr. Rudolf Staudigl is an independent consultant and member of the supervisory board of TÜV Süd AG. He has extensive knowledge of manufacturing, science and international markets with a focus on China and India. As a longtime CEO of Wacker Chemie AG, an international chemical company, he also has deep knowledge of biotechnology products.

Jens Holstein, Chief Financial Officer of BioNTechsaid: “We want to use our financial resources wisely to set the direction for the future development of the company. In the coming years, we will primarily invest in research and development. We expect to reach € 0.4 billion and € 1.5 billion for our ongoing R&D initiatives in 2022 alone, while also aiming to further organic growth, for example through synergistic acquisitions and licensing. “

The rapid development of BioNTech in the past financial year significantly increased the workload of all committees. As this is also to be expected in the financial year 2022, the shareholders accepted the proposal of the Management Board and Supervisory Board regarding separate remuneration for this work. A regular committee member will receive in the future an additional annual fee of EUR 5,000 per committee, and the chairmen of the committees will receive a fee of EUR 15,000 per year, except for the chairman of the audit committee who will receive EUR 30,000 per year.

About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a next-generation immunotherapy company pioneering therapies for cancer and other serious diseases. The company combines a range of state-of-the-art therapeutic platforms and bioinformatics tools to rapidly accelerate the development of new biopharmaceuticals. The diverse portfolio of candidates for oncology products includes individualized therapies as well as mRNA-based drugs, innovative chimeric antigen receptor (CAR) T cells, bispecific checkpoint immunomodulators, targeted anti-cancer antibodies and small molecules. Based on extensive expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech is developing various mRNA vaccine candidates for a range of infectious diseases with collaborative partners in addition to its diverse oncology pipeline. BioNTech works with world-renowned associates in the pharmaceutical industry, including Genmab, Sanofi, Genentech (a Roche group company), Regeneron, Genevant, Fosun Pharma and Pfizer.
For more information, see:

BioNTech Forward-Looking Statements
This press release contains certain forward-looking statements under the revised Private Securities Dispute Resolution Act of 1995, including, but not limited to, statements, whether express or implied, regarding: BioNTech’s financial position and performance in 2021 and its potential benefits The forward-looking statements in this press release are not promises or guarantees and should not be relied upon as they are subject to many known and unknown risks, uncertainties and other factors, many of which are beyond BioNTech’s control and which may cause that actual results will differ materially from those expressed or implied in such forward-looking statements.

A discussion of the risks and uncertainties can be found in the annual report for the year ended December 31, 2021, published as 20-F on March 30, 2022. This is filed with the SEC and is available on the SEC’s website at for disposal. All information contained in this press release is correct at the time of publication and BioNTech makes no commitment to update this information except as required by law.

Media inquiries
Jasmina Alatovic
+49 (0) 6131 9084 1513

investor inquiries
Dr. Sylke Maas
+49 (0) 6131 9084 1074

Selected leveraged products in BioNTech (ADR)With knockouts, speculative investors can disproportionately participate in price movements. Just choose the leverage you want and we’ll show you the right BioNTech (ADR) open products

The leverage must be between 2 and 20

No data

Leave a Comment